Establishment Labs (ESTA) Expected to Announce Earnings on Wednesday

Establishment Labs (NASDAQ:ESTA) will likely be announcing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Establishment Labs to post earnings of ($0.3550) per share and revenue of $57.4470 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The company had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm’s quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.19) EPS. On average, analysts expect Establishment Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA opened at $70.23 on Monday. The company’s 50 day simple moving average is $65.53 and its 200 day simple moving average is $66.03. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -40.36 and a beta of 1.12. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs has a 1 year low of $31.04 and a 1 year high of $83.31.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and issued a $88.00 target price on shares of Establishment Labs in a report on Wednesday, April 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Citigroup dropped their price objective on Establishment Labs from $81.00 to $74.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. Stephens raised their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Canaccord Genuity Group lifted their target price on Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.86.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 42,642 shares of the stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $65.43, for a total value of $2,790,066.06. Following the completion of the transaction, the director directly owned 1,139,862 shares in the company, valued at approximately $74,581,170.66. This represents a 3.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 150,000 shares of company stock worth $9,629,263 in the last three months. 9.99% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Establishment Labs

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new position in Establishment Labs in the 3rd quarter worth about $34,000. Kestra Advisory Services LLC acquired a new stake in shares of Establishment Labs during the fourth quarter valued at about $47,000. Osaic Holdings Inc. grew its holdings in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the last quarter. PharVision Advisers LLC bought a new stake in shares of Establishment Labs during the third quarter worth about $203,000. Finally, Twinbeech Capital LP acquired a new position in shares of Establishment Labs in the fourth quarter valued at approximately $214,000. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.